Adma Biologics Inc · NASDAQ:ADMA
Adma Biologics — Investor Presentation (August 2026)
22 slides from Adma Biologics's investor presentation, August 2026
Slide 1: ADMA Biologics Corporate Presentation
ADMA Biologics Corporate Presentation Realizing the Potential of Specialty Biologics with Groundbreaking Immunotechnology August 2026 NASDAQ: ADMA
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. and its subsidiaries (collectively, “we,” “our” or the “Company”), including, without limitati
Slide 3: Who We Are
Who We Are NASDAQ: ADMA
Slide 4: Who We Are: An Innovative, U.S.-Based Specialty Biologics Company
Who We Are: An Innovative, U.S.-Based Specialty Biologics Company ADMA Biologics is a US-based, end-to-end, vertically integrated biopharma company leading the way as a producer of specialty biologics Manufacturing Campus Corporate Headquarters ADMA BioCenters Headquarters ADMA Biologics ian end-to-
Slide 5: Vertically Integrated U.S.-Based Manufacturing Supply Chain with Innovative Technology
Vertically Integrated U.S.-Based Manufacturing Supply Chain with Innovative Technology ADMA’s end-to-end manufacturing capabilities enable efficiency, visibility and a competitive advantage VERTICALLY INTEGRATED US-BASED SUPPLY CHAIN ~590 FULL-TIME EMPLOYEES, FULLY US-BASED ✓ End-to-end control of c
Slide 6: Vertical Integration: Plasma Collection Centers are Essential to Ensure Raw Material Supply
Vertical Integration: Plasma Collection Centers are Essential to Ensure Raw Material Supply to Produce IG Internal plasma collection capabilities coupled with 3rd party supply contracts support near and long-term revenue growth objectives ADMA BioCenters Collection Network High-Titer Plasma 3rd Part
Slide 7: US IG Landscape
US IG Landscape ne BIOLOGICS \).
Slide 8: Fast Growing Company with Expanding Margins in a Large and Expanding IG Market
Fast Growing Company with Expanding Margins in a Large and Expanding IG Market High Market Demand & Opportunity Despite Decades of IG use, Improved PI is a Significant Market Opportunity2 in the US IG Market1 Therapies Still Needed ‘24-33 • PI is a class of inherited genetic disorders that causes an
Slide 9: ASCENIV – ADMA’s Unique IG Offering
ASCENIV – ADMA’s Unique IG Offering TM ASCENIV: FDA-Approved Protection Against Serious Infections Proven Efficacy in Treating Patients with PI(2) IN A 1-YEAR STUDY OF PATIENTS WITH PI, • Indicated for the treatment of patients with primary immunodeficiency (PI) ASCENIV reported zero serious bacteri
Slide 10: ASCENIV – Making a Positive Difference for Patients with PI
ASCENIV – Making a Positive Difference for Patients with PI TM Compelling Real-World Patient Testimonials Testimonial Highlight: Kyler’s Story “I'm so grateful that I have ASCENIV in my corner” MEET LISA MARIE, 55-year-old nurse, married with a blended “With ASCENIV, I’m looking forward to just bein
Slide 11: High Demand & Growth Opportunity for ASCENIV Within the Broader IG Market
High Demand & Growth Opportunity for ASCENIV Within the Broader IG Market 250,000 DIAGNOSED PI PATIENTS & GROWING (1) Total Prevalence: NIH Estimates ~500K+ Diagnosed and Undiagnosed PI Patients in the U.S. (TAM): TOTAL ADDRESSABLE MARKET ~10% (25K PATIENTS) • Patients with recurrent, breakthrough L
Slide 12: ADMA’s Innovative Commercial Model
ADMA’s Innovative Commercial Model Commercial Infrastructure in Place to ✓ ~40-person commercial team(1) • Significant, identified growth opportunities by SIGNIFICANT way of both increased depth & expanded breadth Support Growth OPPORTUNITIES of prescriber coverage ✓ Call points & end-markets are •
Slide 13: Upside & Growth Opportunities
Upside & Growth Opportunities NASDAQ: ADMA
Slide 14: FDA Approved Production Yield Enhancement
FDA Approved Production Yield Enhancement: First-of-its-kind, FDA approved yield enhancement process enabled by ADMA’s nimble manufacturing footprint and commitment to innovation ✓ FDA approval 1H2025 ✓ Successfully commenced ~20%+ additional IG production yields from commercial scale production usi
Slide 15: Potential Upside Through New Product Pipeline and Label Expansion Opportunities
Potential Upside Through New Product Pipeline and Label Expansion Opportunities NEW PRODUCT PIPELINE & LABEL EXPANSION POTENTIAL HYPERIMMUNE GLOBULIN PIPELINE EXPANSION Attractive new product and label expansion opportunities for specialty IGs • Issued IP for commercial product to screen hyperimmune
Slide 16: Senior Leadership
Senior Leadership NASDAQ: ADMA
Slide 17: Experienced Management Team and Board of Directors
Experienced Management Team and Board of Directors NAME SELECTED CURRENT OR PAST AFFILIATIONS Adam Grossman Founder, President, CEO & Director Kaitlin Kestenberg COO & SVP Compliance Terry Kohler CFO & Treasurer Steven Elms Chairman Dr. Jerrold Grossman Founder & Vice Chairman Lawrence Guiheen Direc
Slide 18: Financials
Financials “<< NASDAQ: ADMA
Slide 19: Forecasted Revenue and Earnings Growth
Forecasted Revenue and Earnings Growth Financial Guidance ~45% adj. EBITDA Margin ~52% adj. EBITDA Margin Highlights • Rapidly growing revenue and earnings growth, with uniquely durable asset base $545mm $510mm • FY 2026 total revenue expected to be $530 million to $560 million +20% +7% Y-o-Y Y-o-Y
Slide 20: Financial Overview
Financial Overview Three Months Ended Three Months Ended Financial Overview $ June 30, 2026 June 30, 2025 (Unaudited) (Unaudited) Revenues $124.4M $122.0M Gross Profit $86.3M $67.2M Adjusted EBITDA(1) $61.8M $50.8M Adjusted Net Income(2) $39.0M $36.0M Basic EPS $0.17 $0.14 Cash and cash equivalents
Slide 21: ADMA Investment Highlights
ADMA Investment Highlights US-Based, End-to-End Controlled Supply Chain 2026 to be first full year of yield enhancement production, providing for 20%+ greater IG output from same starting plasma, enabling significant revenue growth and earnings expansion Diversified & Long-Term Plasma Supply Robust
Slide 22: Appendix - Non-GAAP Reconciliation
Appendix - Non-GAAP Reconciliation Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 (amounts in thousands) March 31, 2025 June 30, 2025 September 30, 2025 December 31, 2025 March 31, 2026 June 30, 2026 Net income $26,904 $34,219 $36,428 $49,379 $45,328 $37,822 Depreciation 1,944 2,027 1,987 1,995 1,7